Found: Pelizaeus-Merzbacher Disease, the Cause, and a Potential Cure

  According to a recent article published by the University of California San Francisco, Pelizaeus-Merzbacher disease (PMD) is a rare neurological disease affecting young boys. PMD fatalities may occur before the child…

Continue Reading Found: Pelizaeus-Merzbacher Disease, the Cause, and a Potential Cure
Company Awarded Grant to Conduct Amyotrophic Lateral Sclerosis Clinical Trial
kschneider2991 / Pixabay

Company Awarded Grant to Conduct Amyotrophic Lateral Sclerosis Clinical Trial

According to a story from PR Newswire, the biopharmaceutical company Clene Nanomedicine, Inc., has issued an announcement in regards to its Australian subsidiary. This subsidiary has been awarded a grant…

Continue Reading Company Awarded Grant to Conduct Amyotrophic Lateral Sclerosis Clinical Trial
Experimental Treatment for Diffuse Intrinsic Pontine Glioma Earns Rare Pediatric Disease Designation
geralt / Pixabay

Experimental Treatment for Diffuse Intrinsic Pontine Glioma Earns Rare Pediatric Disease Designation

According to a story from Biotech 365, the immuno-oncology company Mateon Therapeutics Inc. has recently announced that the company's investigational product candidate OT101 has earned the US Food and Drug…

Continue Reading Experimental Treatment for Diffuse Intrinsic Pontine Glioma Earns Rare Pediatric Disease Designation
FDA Approves Supplementary Treatment For Parkinson’s Disease “Off” Episodes
https://pixabay.com/en/approved-pass-ok-approval-symbol-1726357/

FDA Approves Supplementary Treatment For Parkinson’s Disease “Off” Episodes

A recent publication from the US Food and Drug Administration announced the regulatory authority's approval of Nourianz (generic name istradefylline) for Parkinson's patients during "off" episodes. "Off" episodes are windows…

Continue Reading FDA Approves Supplementary Treatment For Parkinson’s Disease “Off” Episodes
Findings From a Mouse Study Could Have Major Implications for Scleroderma
jarleeknes / Pixabay

Findings From a Mouse Study Could Have Major Implications for Scleroderma

According to a story from Scleroderma News, the results of a recent mouse study could have significant implications for the future of scleroderma treatment. In the study, scientists used a…

Continue Reading Findings From a Mouse Study Could Have Major Implications for Scleroderma
Positive Findings in Phase 2 Study of Refractory Status Epilepticus Drug Candidate
TeroVesalainen / Pixabay

Positive Findings in Phase 2 Study of Refractory Status Epilepticus Drug Candidate

According to a recent press release from the Pennsylvania-based Marinus Pharmaceuticals, the Company is reporting positive results of its phase 2 study of "ganaxolone," an investigational GABAA modulator for patients…

Continue Reading Positive Findings in Phase 2 Study of Refractory Status Epilepticus Drug Candidate
More than 4% of People May be Immunocompromised – How Should They Approach Flu Season?
source: pixabay.com

More than 4% of People May be Immunocompromised – How Should They Approach Flu Season?

A recent publication from Healio detailed some of the challenges immunocompromised individuals might face during flu season. Influenza is a common and sometimes serious public health concern around the world, and…

Continue Reading More than 4% of People May be Immunocompromised – How Should They Approach Flu Season?
Firma Clinical Research Incorporates Patient “Lived Experience” Into Training Materials
5239640 / Pixabay

Firma Clinical Research Incorporates Patient “Lived Experience” Into Training Materials

According to a story from outsourcing-pharma.com, the company Firma Clinical Research, which provides health care services to patients in clinical trials, has been getting a lot of business lately. This…

Continue Reading Firma Clinical Research Incorporates Patient “Lived Experience” Into Training Materials
Potential Treatment for Nonalcoholic Steatohepatitis Earns Fast Track Designation
sms467 / Pixabay

Potential Treatment for Nonalcoholic Steatohepatitis Earns Fast Track Designation

According to a story from sectorpublishingintelligence.co.uk, the drug company INVENTIVA's lead product candidate, known as lanifibranor, has earned Fast Track Designation from the US Food and Drug Administration (FDA) as…

Continue Reading Potential Treatment for Nonalcoholic Steatohepatitis Earns Fast Track Designation
The FDA Approves First Pediatric Treatment for Rare Forms of Vasculitis
qimono / Pixabay

The FDA Approves First Pediatric Treatment for Rare Forms of Vasculitis

According to a story from finanzen.ch, the US Food and Drug Administration (FDA) recently approved the drug rituximab (marketed as Rituxan) as a treatment in child patients aged at least…

Continue Reading The FDA Approves First Pediatric Treatment for Rare Forms of Vasculitis